Multidisciplinary approach in the treatment of metastatic #ProstateCancer . Alicia Morgans, MD, MPH Dana-Farber moderates a discussion and presentation with Robert Dreicer UVA School of Medicine in this independent medical education initiative supported by Loxo@Lilly Oncology Medical > bit.ly/3R6xs8I

Utilization of neoadjuvant chemo before cystectomy. Hiten Patel NM Urology joins Ruchika Talwar Vanderbilt Urology to discuss his team’s study on the use of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive #BladderCancer . #WatchNow > bit.ly/3IQNe2D

Long-term outcomes following fairly brief androgen suppression and stereotactic radiation therapy in high-risk #ProstateCancer : Update from the FASTR/FASTR-2 trials. #BeyondTheAbstract on UroToday > bit.ly/3vqZYdq Glenn Bauman, MD

Distinct mesenchymal cell states mediate #ProstateCancer progression. Massimo Loda Weill Cornell Medicine Pathology and Andrea Miyahira Prostate Cancer Foundation discuss his team’s research on the role of the microenvironment in #PCa progression, published in Nature Communications > bit.ly/4cnAu19 NewYork-Presbyterian

Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix vs leuprolide in adv #ProstateCancer . Exciting findings from the #HERO study reveal insights into ADT options for pts with CV comorbidities. #BeyondTheAbstract > bit.ly/3xklSPR

The role of radiotherapy in the management of squamous cell cancer of the penis. #BeyondTheAbstract with Juanita Crook, MD, FRCPC BC Cancer of work in @WJUrol. #ReadNow on UroToday > bit.ly/4cjm0iQ

PSMA PET imaging and targeted therapies: a case study on high-risk localized #ProstateCancer . Tian Zhang, MD, MHS @UTSWNews and Elena Castro discuss in this Independent Medical Education Initiative on UroToday > bit.ly/3IdC7Rd Bayer | Pharmaceuticals

Advances in #PrecisionMedicine rapidly transforming treatment options for #BladderCancer patients. Daniel Castellano Hospital Universitario 12 de Octubre discusses the importance of multidisciplinary approaches in patient care and research > bit.ly/3SvJ7yD

Urinary minimal residual disease detection predicts recurrence in BCG-unresponsive #NIMBC and quantifies molecular response to nadofaragene firadenovec. Vikram M. Narayan, MD & Sam S. Chang MD, MBA discuss the potential of urinary markers in predicting responses > bit.ly/49sVWzH

How do molecular classifications affect the neoadjuvant treatment of muscle-invasive #UrothelialCarcinoma ? #BeyondTheAbstract with Nicole Conci and Elisa Tassinari. #ReadNow on UroToday > bit.ly/4d9UXH3 Francesco Massari

Prostate Cancer Foundation's guidelines for Black men in the US. Isla Garraway, MD, PhD UCLA Urology joins SamWashUro UC San Francisco to discuss Prostate Cancer Foundation's new screening guidelines addressing the unique risks Black men face, in this discussion on UroToday > bit.ly/3uErHad

Parsing the evidence from the #EMBARK trial on a promising new drug regimen in high-risk nonmetastatic hormone-sensitive #ProstateCancer . Matt Cooperberg UCSF Helen Diller Family Comprehensive Cancer Ctr joins Zach Klaassen Georgia Cancer Center in this conversation on UroToday > bit.ly/3RtOdtt

Delve into the intricate world of Chromophobe #RCC with our latest review! Discover the unique pathogenic mechanisms, potential therapeutic targets, and challenges in advancing research and treatment with Elizabeth Henske and Melissa Daou Brigham and Women's Hospital > bit.ly/3OYqv8s

Novel computational approach identifies NME2-MYC axis as a biomarker and therapeutic target in enzalutamide-resistant #CRPC . Antonina Mitrofanova, PhD SHP_Rutgers joins Andrea Miyahira to discuss her teams research in Nature Communications > bit.ly/4bjJjrz

Advances and challenges in high-risk #CSPC : a multidisciplinary approach to patient management. Paul Sieber joins Neal Shore to discuss risk stratification for patients with hormone-sensitive or castration-sensitive disease > bit.ly/3wrrMOM Bayer | Pharmaceuticals

The #NePtune trial: Evaluating neoadjuvant PARP inhibition in BRCA-mutated #ProstateCancer . Rana McKay UC San Diego and Alicia Morgans, MD, MPH Dana-Farber discuss the aggressive nature of BRCA-mutated PCa earlier in the disease course > bit.ly/4axW8OA

Hot flushes – how can we help our patients? Presented by ONCODOC St Vincent's Sydney. #APCCC24 Written coverage by Zach Klaassen Georgia Cancer Center MCG Urology > bit.ly/3y3YC97 Advanced Prostate Cancer Consensus Conference The Kinghorn Cancer Centre

Amer. Urol. Assn. #AUA24 MedscapeLIVE meeting, Friday, May 3 (6pm CST)👉Join us in person or virtually to discuss the latest in the mHSPC #prostatecancer 👉Latest clinical data & emerging genomic targeted Rx: Registration link👉 tinyurl.com/mryz6kaw Scott Tagawa #DrEvanYu 👇

Darolutamide outcomes in #European patients with #mHSPC from the #ARASENS trial. tombal UCLouvain joins Alicia Morgans, MD, MPH Dana-Farber in this discussion on UroToday > bit.ly/4aODZfQ

Case series explores the link between germline APC I1307K variant and treatment-emergent neuroendocrine #ProstateCancer . Discoveries shed light on potential genetic predictors & underline the need for personalized surveillance strategies > bit.ly/4cwS42D Minas Economides, MD